{"contentid": 488508, "importid": NaN, "name": "Mood music changes as FDA gets tough on early I-O nods", "introduction": "After two days of discussions yielding reaffirmed support for Tecentriq\u00e2\u0080\u0099s (atezolizumab) Accelerated Approvals, the US regulator\u00e2\u0080\u0099s scientific panel changed tack on Thursday, voting to rescind decisions for both Keytruda (pembrolizumab) and Opdivo (nivolumab).", "content": "<p><span style=\"font-weight: 400;\">After two days of discussions yielding&nbsp;</span><a href=\"https://www.thepharmaletter.com/article/more-i-o-early-approvals-bear-scrutiny-of-fda-review\"><span style=\"font-weight: 400;\">reaffirmed support</span></a><span style=\"font-weight: 400;\">&nbsp;for Tecentriq&rsquo;s (atezolizumab) Accelerated Approvals, the US regulator&rsquo;s scientific panel changed tack on Thursday, voting to rescind decisions for both Keytruda (pembrolizumab) and Opdivo (nivolumab).</span></p>\n<p><span style=\"font-weight: 400;\">The three-day series of meetings was called as part of a wider review of Food and Drug Administration nods made under the Accelerated Approval program, where confirmatory data has not been supplied.</span></p>\n<p><span style=\"font-weight: 400;\">While the FDA is not bound by the advisory panel, it tends to follow the decisions reached during such discussions.</span></p>\n<p><span style=\"font-weight: 400;\">The FDA&rsquo;s Oncologic Drugs Advisory Committee (ODAC) voted six to two against keeping Merck &amp; Co&rsquo;s (NYSE: MRK) Keytruda available as a later-line option in gastric and gastroesophageal junction (GEJ) cancer.</span></p>\n<p><span style=\"font-weight: 400;\">While the treatment has been available since 2017 for these patients, data from the KEYNOTE-061 and KEYNOTE-062 trials failed to support the early approval, showing no statistically significant improvement over chemotherapy.</span></p>\n<h2><strong>Hepatocellular carcinoma</strong></h2>\n<p><span style=\"font-weight: 400;\">More narrowly, the panel voted five to four to reverse a decision for Bristol Myers Squibb (NYSE: BMY), which has been offering its immuno-oncology therapy Opdivo as a second-line treatment in liver cancer.</span></p>\n<p><span style=\"font-weight: 400;\">The treatment did not succeed in significantly extending overall survival (OS) for these patients, when used as a first-line treatment in the Phase III CheckMate-459 trial.</span></p>\n<p><span style=\"font-weight: 400;\">By contrast, the panel did vote unanimously to maintain Keytruda&rsquo;s approval in this treatment setting, with Merck&rsquo;s checkpoint blocker being deemed useful for people previously treated with Bayer's (BAYN: DE) Nexavar (sorafenib).</span></p>\n<p><span style=\"font-weight: 400;\">The difference is emblematic of the two checkpoint blocker&rsquo;s divergent fortunes generally, with Opdivo sales declining 3% in the first quarter, while Keytruda powered away with 19% growth.</span></p>\n<p><span style=\"font-weight: 400;\">While sales of Bristol Myers&rsquo; option have remained flat for some time, the therapy still brought in a whopping $7 billion for the company in 2020, with significant prospects remaining in the adjuvant and neoadjuvant settings.</span></p>\n<p><span style=\"font-weight: 400;\">In a now familiar story, Keytruda&rsquo;s growth prospects look even more spectacular, with analysts forecasting peak sales in excess of $28 billion by 2026.</span></p>", "date": "2021-04-30 13:11:00", "meta_title": NaN, "meta_keywords": "panel, treatment, Keytruda, Opdivo, support, Accelerated, discussions, decisions, approval, nods, early, reaffirmed, yielding, days, sales, atezolizumab", "meta_description": "After two days of discussions yielding reaffirmed support for Tecentriq\u00e2\u0080\u0099s (atezolizumab) Accelerated Approvals, the US regulator\u00e2\u0080\u0099s scientific panel changed tack", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 13:10:21", "updated": "2021-04-30 14:05:01", "access": NaN, "url": "https://www.thepharmaletter.com/article/mood-music-changes-as-fda-panel-gets-tough-on-early-i-o-nods", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "keytruda_big.png", "image2id": "keytruda_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Focus On, Regulation, Research, US FDA", "geography_tag": "Switzerland, USA", "company_tag": "Bristol-Myers Squibb, Merck & Co, Roche", "drug_tag": "Keytruda, Opdivo, Tecentriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 13:11:00"}